Health news and discussion on TalkFuse.
Cancer Vaccines Are Advancing. Can Regulators Keep Up?
Two clinical trials reported promising advances in cancer vaccines, which train the immune system to recognise and attack cancer cells. The findings could improve treatment and possibly prevention, while raising questions about whether the US Food and Drug Administration’s evaluation process can keep pace with personalised medicines.
In a trial of 126 people with relapsed acute myeloid leukaemia who had entered remission, recipients of the experimental vaccine galinpepimut-S lived a median of 24 months, compared with 14.7 months for those given other available treatments; full trial data have not yet been released. A separate trial of 1,137 melanoma patients found that 82.2 per cent who received Moderna and Merck’s personalised mRNA vaccine intismeran with pembrolizumab were alive and cancer-free after two years, compared with 70 per cent given pembrolizumab alone. Researchers are also investigating whether vaccines could help prevent pancreatic cancer.
In short
- An experimental leukaemia vaccine was linked to longer median survival.
- A personalised melanoma vaccine reduced the risk of cancer returning.
- Researchers are exploring vaccines to prevent pancreatic cancer.